We now have a RET inhibitor, selpercatinib. This new drug for NSCLC and thyroid cancer is discussed as well as RET in general as a target.

Then, we cover olaparib's latest approval for use in conjunction WITH bevacizumab for maintenance in HRD ovarian cancer based on PAOLA-1 (19:30).

Finally, we run through IMBrave 150 (atezolizumab + bevacizumab) which may establish a new standard of care in HCC (22:20) and briefly discuss olanzapine for cancer-associated N/V and Ivosidenib for IDH1-mutated cholangiocarcninoma.

RET fusions: https://doi.org/10.1016/j.ctrv.2019.101911

PAOLA-1: https://www.nejm.org/doi/full/10.1056/NEJMoa1911361

IMbrave150: https://www.nejm.org/doi/full/10.1056/NEJMoa1915745

Olanzapine: https://jamanetwork.com/journals/jamaoncology/article-abstract/2765323

Ivosidenib in cholangiocarcinoma: https://doi.org/10.1016/S1470-2045(20)30157-1